Bone News and Research

RSS

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

State News: Ga. Senate oks insurance mandates bill; Va. Assembly says abortion clinics should be regulated as hospitals

State agencies, county prosecutors, insurance companies, and health care employers and associations are mandatory reporters — they're required to report potentially dangerous and unprofessional doctors to medical regulators, who can bar the doctors from practicing and keep patients out of harm's way. But the mandatory reporters sound few alarms, and when they do, regulators rarely take action, the Tribune found.

25 Feb 2011

Medtronic acquires chitosan-dextran gel technology for use in functional endoscopic sinus surgery

Medtronic, Inc. today announced that it has completed the purchase of rights to a chitosan-dextran gel technology from Adelaide Research & Innovation Pty Ltd. in Australia, Robinson Squidgel Ltd., and Otago Innovation Ltd. in New Zealand. Medtronic is acquiring this technology for potential use in developing future products for functional endoscopic sinus surgery (FESS).

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

Breast cancer can develop very differently in different women. Researchers in Norway are improving breast cancer diagnostics and treatment by identifying the various tumour types. The objective is to find out as much as possible about the various tumour types so that each patient can receive precisely the right treatment at the right time.

25 Feb 2011

fMRI reveals complexity of consciousness

Using a sophisticated imaging test to probe for higher-level cognitive functioning in severely brain-injured patients provides a window into consciousness -- but the view it presents is one that is blurred in fascinating ways, say researchers at Weill Cornell Medical College in the Feb. 25 online edition of the journal Brain.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.

25 Feb 2011

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

FN-EDA protein can reduce damage after heart attack

Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

25 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Sunesis Pharmaceuticals, Inc. today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.

23 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Researchers to explore genomes of childhood cancers

In a project supported by Genome BC, a Vancouver pediatric pathologist at the BC Cancer Agency/University of British Columbia is leading the team that will explore the genomes of four of the most challenging childhood cancers known.

23 Feb 2011

$Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women$

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found.

23 Feb 2011

FDA clears ArthroCare's Parallax Contour-enhanced Vertebral Augmentation Device

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration to market its second-generation Parallax Contour -enhanced Vertebral Augmentation Device specifically for void creation in a vertebral body followed by injection of bone cement.

22 Feb 2011

Nitroglycerin ointment may help in improving older women’s bone health: Study

A new study has shown that nitroglycerin ointment, that is used for chest pain or angina can be beneficial in postmenopausal women in improving their bone density. In this group of women, the bone becomes increasingly weak and brittle and leads to easy fractures. The study showed that postmenopausal women who used it for 2 years showed a modest increase in bone mineral density and decrease in bone resorption (loss). The study was published in the February 23 issue of JAMA.

22 Feb 2011

Bone News and Research

FDA approves GSK's PROMACTA to treat rare blood disorder

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

State News: Ga. Senate oks insurance mandates bill; Va. Assembly says abortion clinics should be regulated as hospitals

Medtronic acquires chitosan-dextran gel technology for use in functional endoscopic sinus surgery

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

fMRI reveals complexity of consciousness

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

Genentech granted FDA hearing on Avastin for metastatic breast cancer

FN-EDA protein can reduce damage after heart attack

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

MD Anderson physician honored for impact on blood, marrow transplantation

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Researchers to explore genomes of childhood cancers

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

FDA clears ArthroCare's Parallax Contour-enhanced Vertebral Augmentation Device

Nitroglycerin ointment may help in improving older women’s bone health: Study

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News